7.10
-0.14
(-1.93%)
May 17 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 7.03 - 7.25 |
| 52 week | 4.02 - 7.89 |
| Open | 7.25 |
| Vol / Avg. | 86,450.00/55,357.00 |
| Mkt cap | 509.54M |
| P/E | - |
| Div/yield | - |
| EPS | -1.10 |
| Shares | 71.77M |
| Beta | - |
| Inst. own | 11% |
Events
May 14, 2013
Q1 2013 Regulus Therapeutics Earnings Conference Call
Mar 5, 2013
Regulus Therapeutics at Cowen Health Care Conference
Feb 20, 2013
Q4 2012 Regulus Therapeutics Earnings Conference Call
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | -223.26% | -137.07% |
| Operating margin | -225.79% | -136.07% |
| EBITD margin | - | -91.00% |
| Return on average assets | -28.92% | -23.78% |
| Return on average equity | -49.16% | -169.02% |
| Employees | 72 | - |
| Carbon Disclosure Rating | - | - |
Address
Suite 210, 3545 John Hopkins Court
SAN DIEGO, CA 92121
United States - Map
+1-858-2026300 (Phone)
+1-302-6555049 (Fax)
SAN DIEGO, CA 92121
United States - Map
+1-858-2026300 (Phone)
+1-302-6555049 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Volume delayed by 15 mins.
Advertisement
Description
Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing first-in-class drugs that target microRNAs to treat a range of diseases. microRNAs are naturally occurring ribonucleic acid, (RNA), molecules that play a critical role in regulating key biological pathways. The Company uses microRNA product platform to develop chemically modified, single-stranded oligonucleotides which it calls anti-miRs. It uses these anti-miRs to modulate microRNAs and by doing so return diseased cells to their healthy state. In August 2012, the Company formed a strategic alliance with AstraZeneca to discover and develop microRNA therapeutics for cardiovascular diseases, metabolic diseases and oncology.
Officers and directors
| John M. Maraganore Ph.D. | Chairman of the Board | |
| Kleanthis G. Xanthopoulos Ph.D. | President, Chief Executive Officer, Director | |
| Garry E. Menzel Ph.D. | Chief Operating Officer, Executive Vice President - Finance | |
| Neil W. Gibson Ph.D. | Chief Scientific Officer | |
| Mark G. Foletta CPA | Director | |
| B. Lynne Parshall J.D. | Director | |
| William H. Rastetter Ph.D. | Director | |
| Douglas E. Williams Ph.D. | Director | |
| David Baltimore Ph.D. | Independent Director |